Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Global Ankylosing Spondylitis Market Report 2024

Ankylosing Spondylitis Global Market Report 2025 – By Treatment Type (Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery), By Molecule (Biologics, Biosimilar, Small Molecules), By Route of Administration (Parenteral, Oral, Other Routes), By Application (Juveniles, Adults), By End User (Hospitals, Clinics, Research Laboratories, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

Ankylosing Spondylitis Global Market Report 2025

Report Price : $4490.00 | Pages : | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Ankylosing Spondylitis Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Ankylosing Spondylitis Market Definition

Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints (the joints connecting the lower spine to the pelvis). It involves inflammation of the joints and entheses and affects joints, leading to pain, stiffness, and progressive loss of mobility in the spine.

The main treatment of ankylosing spondylitis includes painkillers and non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biological therapies, steroids, and physical therapies, surgery. Painkillers and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) refer to medications that block the production of certain chemicals in the body that cause pain and swelling, which are used in ankylosing spondylitis treatment to relieve pain and reduce inflammation. Biologics, biosimilars, and small molecules are administered through parenteral, oral, and other routes for applications in juveniles and adults by hospitals, clinics, research laboratories, and other end users.

Ankylosing Spondylitis Market Segmentation

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics, Research Laboratories, Other End Users

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

Ankylosing Spondylitis Market Size and growth rate 2025 to 2029: Graph

Ankylosing Spondylitis Market Size 2025 And Growth Rate

The ankylosing spondylitis market size has grown strongly in recent years. It will grow from $5.9 billion in 2024 to $6.36 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to hla-b27 discovery, biologic treatments development, pain management approaches, patient advocacy and awareness, NSAIDS and disease modifying drugs

Ankylosing Spondylitis Market Growth Forecast

The ankylosing spondylitis market size is expected to see strong growth in the next few years. It will grow to $8.71 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to personalized medicine approach, novel biologics development, early intervention and screening, lifestyle and diet management, telemedicine and remote monitoring. Major trends in the forecast period include biosimilar availability, targeted pain therapies, patient-reported outcomes (pros) emphasis, community support programs, regenerative medicine exploration.

Book your 30 minutes free consultation with our research experts

Contact Us

Ankylosing Spondylitis Market Driver: Ankylosing Spondylitis Market Surges With The Growing Geriatric Population Worldwide

The increasing geriatric population is expected to propel the growth of the ankylosing spondylitis market going forward. The geriatric population refers to an increase in the proportion of elderly people due to changes in the age structure of a population. This demographic shift has increased the number and proportion of people over the age of 60. Ankylosing spondylitis treatment and drugs help to improve mobility and manage pain in the geriatric population having ankylosing spondylitis condition. For instance, in January 2023, according to the United Nations Department of Economic and Social Affairs (UN DESA), a US-based department of the UN Secretariat, the global population of individuals aged 65 and older is expected to more than double, increasing from 761 million in 2021 to 1.6 billion by 2050. Therefore, the increasing geriatric population is driving the growth of the ankylosing spondylitis market.

Ankylosing Spondylitis Market Driver: Escalating Instances Of Autoimmune Diseases Propel The Ankylosing Spondylitis Market

The increase in instances of autoimmune diseases will boost the ankylosing spondylitis market going forward. Autoimmune diseases are a broad group of disorders characterized by an abnormal immune response in which the immune system mistakenly attacks and damages healthy cells, tissues, and organs. Autoimmune diseases, including ankylosing spondylitis, occur when the immune system mistakenly targets the body's own tissues, leading to inflammation and damage, with genetic predisposition and environmental factors contributing to the development of ankylosing spondylitis, a form of autoimmune arthritis primarily affecting the spine and pelvis. For instance, in September 2023, according to the Impact of IBD Report 2023 published by the IBD Clinical and Research Centre, a Canada-based organization that aims to improve the lives of patients with Crohn's disease and ulcerative colitis, with a prevalence of 825 per 100,000 in 2023, over 320,000 people in Canada have inflammatory bowel disease (IBD), and as the prevalence is expected to increase by 2.44% annually, 1.1% of the population, or 470,000 Canadians, is projected to be living with IBD by 2035. Therefore, the increase in instances of autoimmune diseases will drive the future growth of the ankylosing spondylitis market.

Global Ankylosing Spondylitis Market Major Players

Major companies operating in the ankylosing spondylitis market include Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Cedars-Sinai, Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., UCSF Health, Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

Global Ankylosing Spondylitis Market Trend: Advancements In Therapeutic Options Drive Growth In The Ankylosing Spondylitis Market

The advancements in therapeutic options are a key trend gaining popularity in the ankylosing spondylitis market. Companies operating in ankylosing spondylitis are advancing new therapeutic options to sustain their position in the market. For instance, in April 2022, AbbVie Inc., a US-based biopharmaceutical company, announced the approval of RINVOQ by the U.S. Food and Drug Administration (FDA) for the treatment of adults with active ankylosing spondylitis (AS). This provides a new oral treatment option for patients who have not responded to TNF blockers, showing significant improvement in disease symptoms such as back pain and physical function. Its rapid efficacy and safety profile from clinical trials make it a valuable advancement in managing this chronic inflammatory condition, expanding the therapeutic choices available for patients.

Global Ankylosing Spondylitis Market Trend: Focus On Enzymatic And Cellular Assays For Targeted Therapies

Major companies operating in ankylosing spondylitis are focused on developing innovative drugs such as drugs based on enzymatic and cellular assays for the treatment of moderately to severely active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Drugs based on enzymatic and cellular assays are pharmaceuticals developed and validated through testing their effects on specific enzymes or cell systems, enabling targeted and precise therapeutic interventions. For instance, in April 2022, AbbVie Inc., a US-based pharmaceutical company, received Food and Drug Administration (FDA) approval, this time for the treatment of ankylosing spondylitis (AS). RINVOQ, a selective JAK inhibitor undergoing investigation across various immune-mediated inflammatory diseases, exhibits heightened inhibitory potency for JAK-1 over JAK-2, JAK-3, and TYK-2 based on enzymatic and cellular assays.

Ankylosing Spondylitis Market Merger And Acquisition: Superior And Coherus Partner To Distribute Affordable YUSIMRY For Autoimmune Conditions

In July 2023, Superior Biologics, Inc., a US-based specialty pharmacy and home infusion therapy service company, and Coherus BioSciences, Inc., announced a national distribution agreement. This partnership aims to provide nationwide distribution of YUSIMRY, a biosimilar of Humira, offering patients a high-quality, affordable treatment for conditions like ankylosing spondylitis, rheumatoid arthritis, and Crohn's disease, while helping employers reduce specialty drug costs by over 85%. Coherus BioSciences Inc. is a US-based biopharmaceutical company providing a biosimilar product for ankylosing spondylitis (AS) called YUSIMRY (adalimumab-aqvh).

Regional Outlook For The Global Ankylosing Spondylitis Market

North America was the largest region in the ankylosing spondylitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ankylosing spondylitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ankylosing Spondylitis Market?

The ankylosing spondylitis market consists of sales of nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs), tumor necrosis factor (TNF) inhibitors, interleukin inhibitors, and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Ankylosing Spondylitis Industry?

The ankylosing spondylitis market research report is one of a series of new reports from The Business Research Company that provides ankylosing spondylitis market statistics, including ankylosing spondylitis industry global market size, regional shares, competitors with an ankylosing spondylitis market share, detailed ankylosing spondylitis market segments, market trends and opportunities, and any further data you may need to thrive in the ankylosing spondylitis industry. This ankylosing spondylitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ankylosing Spondylitis Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $6.36 billion
Revenue Forecast In 2034 $8.71 billion
Growth Rate CAGR of 8.2% from 2024 to 2033
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery
2) By Molecule: Biologics, Biosimilar, Small Molecules
3) By Route Of Administration: Parenteral, Oral, Other Routes
4) By Application: Juveniles, Adults
5) By End User: Hospitals, Clinics, Research Laboratories, Other End Users Subsegments: 1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs
2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs
3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors
4) By Steroids: Oral Steroids, Injectable Steroids
5) By Physical Therapies: Physiotherapy, Exercise Programs 6) By Surgery: Joint Replacement Surgery, Spinal Surgery
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Cedars-Sinai, Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., UCSF Health, Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Ankylosing Spondylitis Market Characteristics

    3. Ankylosing Spondylitis Market Trends And Strategies

    4. Ankylosing Spondylitis Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

    5. Global Ankylosing Spondylitis Growth Analysis And Strategic Analysis Framework

    5.1. Global Ankylosing Spondylitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Ankylosing Spondylitis Market Growth Rate Analysis

    5.4. Global Ankylosing Spondylitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Ankylosing Spondylitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Ankylosing Spondylitis Total Addressable Market (TAM)

    6. Ankylosing Spondylitis Market Segmentation

    6.1. Global Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

    Disease-Modifying Anti-Rheumatic Drugs (DMARDS)

    Biological Therapies

    Steroids

    Physical Therapies

    Surgery

    6.2. Global Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Biologics

    Biosimilar

    Small Molecules

    6.3. Global Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Parenteral

    Oral

    Other Routes

    6.4. Global Ankylosing Spondylitis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Juveniles

    Adults

    6.5. Global Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospitals

    Clinics

    Research Laboratories

    Other End Users

    6.6. Global Ankylosing Spondylitis Market, Sub-Segmentation Of Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Over-The-Counter NSAIDs

    Prescription NSAIDs

    6.7. Global Ankylosing Spondylitis Market, Sub-Segmentation Of Disease-Modifying Anti-Rheumatic Drugs (DMARDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Conventional DMARDs

    Targeted DMARDs

    6.8. Global Ankylosing Spondylitis Market, Sub-Segmentation Of Biological Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    TNF Inhibitors

    IL-17 Inhibitors

    6.9. Global Ankylosing Spondylitis Market, Sub-Segmentation Of Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Oral Steroids

    Injectable Steroids

    6.10. Global Ankylosing Spondylitis Market, Sub-Segmentation Of Physical Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Physiotherapy

    Exercise Programs

    6.11. Global Ankylosing Spondylitis Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Joint Replacement Surgery

    Spinal Surgery

    7. Ankylosing Spondylitis Market Regional And Country Analysis

    7.1. Global Ankylosing Spondylitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Ankylosing Spondylitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Ankylosing Spondylitis Market

    8.1. Asia-Pacific Ankylosing Spondylitis Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Ankylosing Spondylitis Market

    9.1. China Ankylosing Spondylitis Market Overview

    9.2. China Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Ankylosing Spondylitis Market

    10.1. India Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Ankylosing Spondylitis Market

    11.1. Japan Ankylosing Spondylitis Market Overview

    11.2. Japan Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Ankylosing Spondylitis Market

    12.1. Australia Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Ankylosing Spondylitis Market

    13.1. Indonesia Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Ankylosing Spondylitis Market

    14.1. South Korea Ankylosing Spondylitis Market Overview

    14.2. South Korea Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Ankylosing Spondylitis Market

    15.1. Western Europe Ankylosing Spondylitis Market Overview

    15.2. Western Europe Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Ankylosing Spondylitis Market

    16.1. UK Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Ankylosing Spondylitis Market

    17.1. Germany Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Ankylosing Spondylitis Market

    18.1. France Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Ankylosing Spondylitis Market

    19.1. Italy Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Ankylosing Spondylitis Market

    20.1. Spain Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Ankylosing Spondylitis Market

    21.1. Eastern Europe Ankylosing Spondylitis Market Overview

    21.2. Eastern Europe Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Ankylosing Spondylitis Market

    22.1. Russia Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Ankylosing Spondylitis Market

    23.1. North America Ankylosing Spondylitis Market Overview

    23.2. North America Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Ankylosing Spondylitis Market

    24.1. USA Ankylosing Spondylitis Market Overview

    24.2. USA Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Ankylosing Spondylitis Market

    25.1. Canada Ankylosing Spondylitis Market Overview

    25.2. Canada Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Ankylosing Spondylitis Market

    26.1. South America Ankylosing Spondylitis Market Overview

    26.2. South America Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Ankylosing Spondylitis Market

    27.1. Brazil Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Ankylosing Spondylitis Market

    28.1. Middle East Ankylosing Spondylitis Market Overview

    28.2. Middle East Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Ankylosing Spondylitis Market

    29.1. Africa Ankylosing Spondylitis Market Overview

    29.2. Africa Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Ankylosing Spondylitis Market Competitive Landscape And Company Profiles

    30.1. Ankylosing Spondylitis Market Competitive Landscape

    30.2. Ankylosing Spondylitis Market Company Profiles

    30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Johnson & Johnson Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

    31. Ankylosing Spondylitis Market Other Major And Innovative Companies

    31.1. Bristol-Myers Squibb

    31.2. Eli Lilly and Company

    31.3. Gilead Sciences Inc.

    31.4. Boehringer Ingelheim International GmbH

    31.5. Amgen Inc.

    31.6. Cedars-Sinai

    31.7. Viatris Inc.

    31.8. Astellas Pharma Inc.

    31.9. AstraZeneca plc

    31.10. UCB Inc.

    31.11. Cipla Inc.

    31.12. Zydus Lifesciences Limited

    31.13. Celltrion Inc.

    31.14. Hetero Labs Ltd.

    31.15. UCSF Health

    32. Global Ankylosing Spondylitis Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Ankylosing Spondylitis Market

    34. Recent Developments In The Ankylosing Spondylitis Market

    35. Ankylosing Spondylitis Market High Potential Countries, Segments and Strategies

    35.1 Ankylosing Spondylitis Market In 2029 - Countries Offering Most New Opportunities

    35.2 Ankylosing Spondylitis Market In 2029 - Segments Offering Most New Opportunities

    35.3 Ankylosing Spondylitis Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Ankylosing Spondylitis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Ankylosing Spondylitis Market, Sub-Segmentation Of Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Ankylosing Spondylitis Market, Sub-Segmentation Of Disease-Modifying Anti-Rheumatic Drugs (DMARDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Ankylosing Spondylitis Market, Sub-Segmentation Of Biological Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Ankylosing Spondylitis Market, Sub-Segmentation Of Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Ankylosing Spondylitis Market, Sub-Segmentation Of Physical Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Ankylosing Spondylitis Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Ankylosing Spondylitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Global Ankylosing Spondylitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Asia-Pacific, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: Asia-Pacific, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: China, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: China, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: India, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: India, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Japan, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Japan, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Australia, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Australia, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Indonesia, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Indonesia, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: South Korea, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: South Korea, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Western Europe, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Western Europe, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: UK, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: UK, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Germany, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Germany, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: France, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: France, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Italy, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Italy, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Spain, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Spain, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Eastern Europe, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Eastern Europe, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Russia, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: Russia, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: North America, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: North America, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: USA, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: USA, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Canada, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Canada, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: South America, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: South America, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Brazil, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Brazil, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Middle East, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Middle East, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Africa, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: Africa, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 82: Pfizer Inc. Financial Performance
  • Table 83: Johnson & Johnson Pvt. Ltd. Financial Performance
  • Table 84: Merck & Co. Inc. Financial Performance
  • Table 85: AbbVie Inc. Financial Performance
  • Table 86: Novartis AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Ankylosing Spondylitis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Ankylosing Spondylitis Market, Sub-Segmentation Of Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Ankylosing Spondylitis Market, Sub-Segmentation Of Disease-Modifying Anti-Rheumatic Drugs (DMARDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Ankylosing Spondylitis Market, Sub-Segmentation Of Biological Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Ankylosing Spondylitis Market, Sub-Segmentation Of Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Ankylosing Spondylitis Market, Sub-Segmentation Of Physical Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Ankylosing Spondylitis Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Ankylosing Spondylitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Global Ankylosing Spondylitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Asia-Pacific, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: Asia-Pacific, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: China, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: China, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: India, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: India, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Japan, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Japan, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Australia, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Australia, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Indonesia, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Indonesia, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: South Korea, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: South Korea, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Western Europe, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Western Europe, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: UK, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: UK, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Germany, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Germany, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: France, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: France, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Italy, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Italy, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Spain, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Spain, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Eastern Europe, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Eastern Europe, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Russia, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: Russia, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: North America, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: North America, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: USA, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: USA, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Canada, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Canada, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: South America, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: South America, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Brazil, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Brazil, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Middle East, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Middle East, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Africa, Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: Africa, Ankylosing Spondylitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 82: Pfizer Inc. Financial Performance
  • Figure 83: Johnson & Johnson Pvt. Ltd. Financial Performance
  • Figure 84: Merck & Co. Inc. Financial Performance
  • Figure 85: AbbVie Inc. Financial Performance
  • Figure 86: Novartis AG Financial Performance

Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis

Read More

How Will The Nuclear Medicine Market Grow In 2022?

Read More

What Is The Pediatric Imaging Market Overview In 2022?

Read More

Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company

Read More

The Business Research Company offers the hospital acquired infection control market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the multiplex assays market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the healthcare it consulting market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth

Read More

Personal Care Shower And Bath Global Market Report 2025 – By Product Type (Shower Cream or Gel, Bar Soap, Body Wash, Shower Oil, Bath Additives, Other Product Types), By Form (Solid, Gel and Jellies, Liquid, Other forms), By Distribution Channel (Supermarkets and Hypermarkets, Convenience Stores, Online Retail Stores, Other Distribution Channels), By End-Users (Men, Women) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Luxury Hair Care Products Global Market Report 2025 – By Product Type (Shampoos, Conditioners, Hair Coloring Products, Hair Styling Products, Hair Oil, Other Product Types), By Distribution Channel (Supermarkets and Hypermarkets, Departmental Stores, Specialty Stores, E-commerce, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Natural Skin Care Products Global Market Report 2025 – By Product (Facial Care, Body Care), By Type (Mass, Premium), By Distribution Channel (Direct Selling, Other Distribution Channels), By End Use (Men, Women, Children) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Natural Hair Care Products Global Market Report 2025 – By Product Type (Shampoos, Conditioners, Oils And Serum, Gel And Wax, Hair Color, Other Product Types), By Gender (Men, Women, Other Genders), By Price Category (High Or Premium, Medium, Low), By Distribution Channel (Offline, Online) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Organic Skincare Global Market Report 2025 – By Type (Facial Care, Body Care, Other Types), By Gender (Male, Female), By Distribution Channel (Supermarkets or Hypermarket, Convenience Stores, Specialist Stores, Online Retail Stores, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Hair Preparations Global Market Report 2025 – By Type (Hair Spray, Conditioner, Shampoo, Hair Oil, Hair Color, Other Types), By Gender (Male, Female, Unisex), By Based On Type (Organic, Chemical), By Distribution Channel (Hypermarkets/Supermarkets, Specialty Stores, Online Stores, Convenience Stores, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Personal Care Ingredients Global Market Report 2025 – By Ingredients (Emollients, Surfactants, Emulsifiers, Rheology Modifiers, Conditioning Polymers, Other Ingredients), By Source (Natural Ingredients, Synthetic Ingredients), By Application (Skin Care, Hair Care, Oral Care, Cosmetics, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Retail And Wholesale Global Market Report 2025 – By Type (Retail, Wholesale), By Ownership (Retail Chain/Wholesale Chain, Independent Retailer/Independent Wholesalers), By Price Range (Premium, Mid Range, Economy), By Distribution Channel (Supermarkets/Hypermarkets, Convienience Stores, Department Stores, Specialty Stores, Online, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Ankylosing Spondylitis market?

Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints (the joints connecting the lower spine to the pelvis). It involves inflammation of the joints and entheses and affects joints, leading to pain, stiffness, and progressive loss of mobility in the spine. For further insights on the Ankylosing Spondylitis market, request a sample here

How will the Ankylosing Spondylitis market drivers and restraints affect the market dynamics? What forces will shape the Ankylosing Spondylitis industry going forward?

The Ankylosing Spondylitis market major growth driver - Ankylosing Spondylitis Market Surges With The Growing Geriatric Population Worldwide. For further insights on the Ankylosing Spondylitis market, request a sample here

What is the forecast market size or the forecast market value of the Ankylosing Spondylitis market?

The Ankylosing Spondylitis market size has grown strongly in recent years. The ankylosing spondylitis market size has grown strongly in recent years. It will grow from $5.9 billion in 2024 to $6.36 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to hla-b27 discovery, biologic treatments development, pain management approaches, patient advocacy and awareness, NSAIDS and disease modifying drugs The ankylosing spondylitis market size is expected to see strong growth in the next few years. It will grow to $8.71 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to personalized medicine approach, novel biologics development, early intervention and screening, lifestyle and diet management, telemedicine and remote monitoring. Major trends in the forecast period include biosimilar availability, targeted pain therapies, patient-reported outcomes (pros) emphasis, community support programs, regenerative medicine exploration. For further insights on the Ankylosing Spondylitis market, request a sample here

How is the Ankylosing Spondylitis market segmented?

The ankylosing spondylitis market covered in this report is segmented –
1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery
2) By Molecule: Biologics, Biosimilar, Small Molecules
3) By Route Of Administration: Parenteral, Oral, Other Routes
4) By Application: Juveniles, Adults
5) By End User: Hospitals, Clinics, Research Laboratories, Other End Users Subsegments:
1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs
2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs
3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors
4) By Steroids: Oral Steroids, Injectable Steroids
5) By Physical Therapies: Physiotherapy, Exercise Programs
6) By Surgery: Joint Replacement Surgery, Spinal Surgery For further insights on the Ankylosing Spondylitis market, request a sample here

Which region has the largest share of the Ankylosing Spondylitis market? What are the other regions covered in the report?

North America was the largest region in the ankylosing spondylitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Ankylosing Spondylitis market, request a sample here.

Who are the major players in the Ankylosing Spondylitis market?

Major companies operating in the ankylosing spondylitis market include Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Cedars-Sinai, Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., UCSF Health, Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd. . For further insights on the Ankylosing Spondylitis market, request a sample here.

What are the key trends in the Ankylosing Spondylitis market?

Major trends in the Ankylosing Spondylitis market include Advancements In Therapeutic Options Drive Growth In The Ankylosing Spondylitis Market. For further insights on the Ankylosing Spondylitis market, request a sample here.

What are the major opportunities in the Ankylosing Spondylitis market? What are the strategies for the Ankylosing Spondylitis market?

For detailed insights on the major opportunities and strategies in the Ankylosing Spondylitis market, request a sample here.

How does the Ankylosing Spondylitis market relate to the overall economy and other similar markets?

For detailed insights on Ankylosing Spondylitis's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Ankylosing Spondylitis industry?

For detailed insights on the mergers and acquisitions in the Ankylosing Spondylitis industry, request a sample here.

What are the key dynamics influencing the Ankylosing Spondylitis market growth? SWOT analysis of the Ankylosing Spondylitis market.

For detailed insights on the key dynamics influencing the Ankylosing Spondylitis market growth and SWOT analysis of the Ankylosing Spondylitis industry, request a sample here.